Actarit

Actarit (4-Acetylaminophenylacetic acid) is an orally active Carbonic Anhydrase II (CAII) inhibitor with an IC50 of 422 nM. Actarit shows suppressive effects experimental autoimmune encephalomyelitis in rats. Actarit inhibits the development of type ll collagen (CII) -induced arthritis in mice by suppressing delayed-type hypersensitivity to CII. Actarit can be used for the study of Multiple Sclerosis (MS) and rheumatoid arthritis[1][2][3][4].

Product Specifications

CAS Number

[18699-02-0]

Product Name Alternative

4-Acetylaminophenylacetic acid; MS-932

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Carbonic Anhydrase; IFNAR; TNF Receptor

Type

Reference compound

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/actarit.html

Concentration

10mM

Purity

99.58

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(C)NC(C=C1)=CC=C1CC(O)=O

Molecular Formula

C10H11NO3

Molecular Weight

193.20

Precautions

H302, H315, H319, H335

References & Citations

[1]Kawai K, et al. Suppressive effects of 4-acetylaminophenylacetic acid (actarit) on experimental autoimmune encephalomyelitis in rats. Immunopharmacology. 1998 May;39 (2) :127-38. |[2]Fujisawa H, et al. Effect of actarit on type II collagen-induced arthritis in mice. Arzneimittel-forschung, 01 Jan 1994, 44 (1) :64-68. |[3]Ghislat G, et al. Identification and Validation of Carbonic Anhydrase II as the First Target of the Anti-Inflammatory Drug Actarit. Biomolecules. 2020 Nov 19;10 (11) :1570. |[4]Fujisawa H, et al. Suppressive effect of actarit on IgA production in mice: activation of CD4+ suppressor T-cells in Peyer's patches. Int J Immunopharmacol. 1995 Jul;17 (7) :611-7.